Idactamab INT-001 represents an interesting medicinal approach for combating certain oncological tumors. The immunoglobulin shows a distinct mode of action, particularly targeting CD38, an cell-surface protein https://prbookmarkingwebsites.com/story28219306/idacta-mab-int-001-a-innovative-antibody-during-progression